Uterine leiomyomas (ULs) are benign tumors that are a major burden to women's health. A genome-wide association study on 5,417 UL cases and 331,791 controls was performed, followed by replication of the genomic risk in two cohorts. Effects of the identified risk alleles were evaluated in view of molecular and clinical features.
INTRODUCTION
Uterine leiomyomas (ULs), also known as fibroids or myomas, are benign smooth muscle tumors of the uterine wall. They are extremely common; approximately 70% of women develop ULs before menopause 1 . The symptoms, occurring in one fifth of women, include excessive menstrual bleeding, abdominal pain and pregnancy complications 1 . In most cases, durable treatment options are invasive 2 . ULs cause a substantial human and economic burden, and the annual cost of treating these tumors has been approximated to be as high as $34 billion in the United States, higher than the combined cost of treating breast and colon cancer 3 .
Earlier studies have indicated strong genetic influence in UL susceptibility based on linkage 4 , population disparity 5 and twin studies 6 . The most striking UL predisposing condition thus far . Further UL predisposition loci have been suggested at 1q42.2 and 2q32.2 by Zhang et al. 13 and, at 3p21.31, 10p11.21 and 17q25.3
by Eggert et al. 14 A recent work reported cytohesin 4 ( CYTH 4) at 22q13.1 as a novel candidate locus in African Americans 15 . While multiple loci and genes have been implicated through these valuable studies it is not straightforward to connect any of them mechanistically to UL development.
Most ULs show somatic site-specific mutations at exons 1 and 2 of the mediator complex subunit 12 ( MED12 ) gene 16, 17 . These observations together with further scrutiny of driver mutations, chromosomal aberrations, gene expression, and clinicopathological characteristics have lead to identification of at least three mutually exclusive UL subtypes; MED12 mutant, Fumarate Hydratase deficient, as well as HMGA2 overexpressing lesions 18 .
Here we report the most powerful GWAS on uterine leiomyoma to date, and novel genome-wide significant UL susceptibility loci with plausible adjacent culprit genes 
Patient and tumor material
Our in-house patient and tumor data were investigated regarding the identified risk loci.
Clinical background data for the number of ULs (Fig. S1 ) and age at hysterectomy (Fig. S2) were available for 357 patients in the Helsinki cohort. All tumors of ≥1cm diameter had been harvested and stored fresh-frozen, and MED12 -mutation status was screened from all 1,165 tumors. Gene expression was studied in an 1Mb flank from each SNP of interest using 60 tumors and 56 respective normal myometrium samples. DNA methylation was studied in an 1Mb flank using 56 tumors and 36 normals. Telomere length estimates derived from whole genome sequencing data were available for 37 UL and 28 myometrium samples. The study 
Statistical analysis
For GWAS, P<5⨉10 -8 was reported as significant. The GRS association tests (Table S6) were controlled for family-wise error rate (FWER) and reported significant for Holm-Bonferroni adjusted P<0.05. Other families of association tests were controlled for false discovery rate (FDR; Benjamini-Hochberg method) and noted significant at FDR<10%.
RESULTS

Identification of predisposition loci
At discovery stage 11 SNPs emerging from five distinct genetic loci passed the genome-wide significance level of 5⨉10 ). The association results are given in Table S1 , and the lead SNPs are summarized in Table 1 . 
Genomic risk score
A polygenic risk score 20 ).
Meta-analysis
The second stage GWAS combined the UKBB and Helsinki cohorts for a meta-analysis approach. We utilized the genome-wide statistics available for a total of 5,168 self-reported UL cases (Neale lab data; details in Supplementary Methods). rs117245733 at 13q14.11 was identified as the only SNP with a suggestive (P<10 -6 ) association in both the UKBB (OR=1.34; P=3.31⨉10 -6 ) and Helsinki (OR=1.82; P=8.12⨉10 ). Fig. 3 shows the regional structure and combined association at the locus: the SNP resides on a gene poor region, at a conserved element that has activity in uterus-specific H3K27ac and DNaseI data (see ENCODE track details in Supplementary Methods). Summary of the meta-analysis results is given in Table S2 . The SNP rs117245733 at 13q14.11 -weighted by its UKBB log-odds -was appended to the initial GRS model. The final GRS model of nine SNPs and their UKBB-based weights is given in Table S3 .
Replication of the GWAS and GRS
The third stage replicated the observations in NFBC. The SNP identified in the stage 2 meta-analysis, rs117245733 at 13q14.11, was replicated with a nominal P=0.034 (linear mixed model; OR=1.50; 95% CI 1.03-2.19). All SNPs except rs11031736 at 11p13 had the same effect direction as observed in UKBB, however, none of the single-SNP associations in NFBC held with multiple testing (Table S4 ). The association between the GRS and UL phenotype replicated with a significant P=1.7⨉10 UL susceptibility is known to vary by ancestry 5 . We computed population specific estimates for the GRS based on the gnomAD database allele frequencies. Fig. S5 shows the resulting estimates for reference (details in Table S7 ). 
Association to clinical variables
The number of ULs per patient had a significant positive association to the GRS (negative binomial regression P=0.0047; adjusted P=0.024; rate ratio 1.61; 95% CI 1.07-2.44 for one-unit increase in GRS; Fig. S6 ). No association was found between the GRS and age at hysterectomy (Table S6 ). Tests for each SNP separately are given in Table S5 .
Association to MED12 mutated tumors
Our UL set of 1165 lesions included 931 (80%) mutation-positive and 234 mutation-negative tumors. the occurrence of mutant tumors did not distribute evenly among the 357 patients. In total 178 (50%) and 96 (27%) patients had all their tumors identified as either MED12 -mutation-positive or -negative, respectively (Fig. S7 ), suggesting that genetic or environmental factors contribute to the preferred UL type in an affected individuals, as previously observed 16 . Indeed, mutation positive patients were found to have a significantly higher GRS (Wilcoxon rank-sum P=0.005; adjusted P=0.024; two-sided; W=6803). This difference in GRS distributions is visualized in Fig. S5 .
Strikingly, comparison against the population controls (n=15,943) revealed an opposite effect direction for the above-mentioned patient groups: the MED12-mutation-positive (178) subset of patients displayed an odds ratio of 2.34 for one-unit increase in GRS (95% CI 1.32-4.15) compared to the controls, and the mutation-negative (96) subset an odds ratio of 0.66 (95% CI 0.28-1.54) compared to the controls. Thus, the majority of the compiled case-control association signal had arisen from the MED12 -mutation-positive subset of the patients. The number of MED12 -mutation-positive tumors per patient also had a significant positive association to the GRS (negative binomial model P=0.0026; adjusted P=0.018; rate ratio 2.08; 95% CI 1.13-3.83 for one-unit increase in GRS; Fig. S8 ). No association between the number of MED12 -mutation-negative tumors and GRS was found (Fig. S8) . Tests for each SNP separately are given in Table S5 .
Association to gene expression
In , Fig. S11 ). WNT4 and ALPL are in adjacent TADs (Fig. 4C) . In normal myometria, no cis-eQTL passed the 10% FDR. Altogether 11 genes in tumors and 8 genes in normals passed with a nominal P<0.05 (Table S8) 10% FDR. Of the plausible culpit genes, TERT , WT1 and WNT4 showed most significant meQTL associations. 18 of the meQTLs in these genes were detectable both in tumors and normals (Table S9 ). All the cis-meQTLs and annotation for their genomic context are in Supplementary Data 3. The association of selected meQTLs with expression is shown in Fig.   S12 -S13.
Association to telomere length
When examining telomere lengths in tumors from carriers and noncarriers of the TERT risk allele, the risk allele (rs2736100) was significantly associated with a shorter telomere length (Kruskal-Wallis P=0.01) (Fig. S14) . The association was not seen in myometrium. Overall the telomere length was significantly shorter in tumors than normals (P=0.01), as previously reported 21, 22 . Adjusting for the patient age did not explain away the association in tumor data.
No association was detected between the genotype and the number of somatic structural variants.
Previously proposed UL predisposition loci
Previous UL association studies 9,13-15 have reported altogether seven genome-wide significant UL susceptibility loci. Two out of the seven loci -that is, 22q13.1 (at TNRC6B ) and 11p15.5
(at BET1L ) -replicated in the UKBB summary statistics for 5,168 self-reported UL cases (Neale lab data). See Table S10 for a summary of these results. 
DISCUSSION
The UK Biobank genotype-phenotype data revealed five novel predisposition loci for UL in close proximity of highly plausible culprit genes. A meta-analysis of the UKBB and Helsinki cohorts identified a sixth novel locus at 13q14.11, residing within a conserved element that has enhancer activity in uterus-specific experiments (Fig. 3) . Two previously reported loci, at , were also validated, and are indeed linked to UL predisposition.
For the three latter loci mechanistic connection to UL is obscure at present.
Though simple association is not sufficient to formally prove causality, the five new risk genes implicated in the discovery phase of this study, ESR1, WT1, WNT4, ATM and TERT, form a robust set of likely culprits.
Estrogen is a well known inducer of UL growth
24
. The top association at 6q25.2 (rs11751190) resides within intron 23 of Spectrin Repeat Containing Nuclear Envelope Protein 1 ( SYNE1 ), 130kb downstream of ESR1 , the latter being the only gene that resides completely within the TAD (Fig. 2C) . While the role of estrogen in leiomyomagenesis has been firmly established, this is the first genetic evidence to this end.
WT1 and WNT4 are central factors in uterine development 25, 26 , and perturbations in their function are known to have neoplastic potential. The strongest association at 11p13 (rs2057178) maps to an intergenic region, 45kb downstream of the closest gene WT1 and the region has active enhancer activity in uterus (Fig. 2B ). WT1 is a transcription factor that acts as both a tumor suppressor and an oncogene ( CDC42 ) and roughly 50kb downstream of WNT4 . While CDC42 cannot be dismissed as a candidate gene, tumor derived data suggests WNT4 as the more plausible target. The risk allele at rs61778046 was associated with upregulation of WNT4 (Fig. 4B) ATM and TERT could be involved in uterine neoplasia predisposition through genetic instability. The lead SNP at 11q22.3 is a nonsynonymous variant (rs1800057; p.Pro1054Arg) in exon 22 of ATM . This SNP was recently highlighted in a renal cell carcinoma GWAS 32 .
ATM is involved in DNA damage response 33 and is one of the relatively few genes that have been found to be recurrently mutated in leiomyosarcoma 34 . TERT encodes a subunit of the telomerase enzyme, which guards chromosomal stability by elongating telomeres. It is expressed in germ cells as well as in many types of cancers 35 . The risk allele at the TERT intron 2 (5p15.33; rs2736100) has several associated cis-meQTLs in the 1Mb flank region (Fig. S9-S10 ). For example CpG chr5:1277576 in the sixth intron of TERT and CpG documented, previous studies have reported contradicting observations on its effect on telomere length [36] [37] [38] [39] [40] . ULs have been shown to display shortened telomeres 21, 22 , potentially provoking chromosomal instability as the chromosome tips are worn out. Our data shows that this finding is explained by TERT risk allele carrier status (Fig. S14) .
GRS associated merely with a susceptibility to the most common UL subtype, MED12 mutation positive tumors. Indeed it has been known that MED12 -mutation-positive tumors do not distribute randomly among patients 16 , and our data provide at least a partial explanation to this intriguing finding. It may be that environmental factors contribute more significantly to genesis of MED12 wild type lesions. In our recent study this tumor type was associated with history of pelvic inflammatory disease, and thus infectious agents could be one underlying factor 41 . Obviously, also the power of GWAS to detect genetic associations to more rare UL types is reduced. Much additional work is needed to fully elucidate the mechanisms connecting the risk alleles and emergence of MED12 mutant UL.
This work highlights several new genetic cornerstones of UL formation, and represents another step towards a much improved understanding of its molecular basis. The GRS score can stratify the female population to low-risk and high-risk quartiles that differ two-fold by their UL risk. While the increased risk appears minor on individual level, the population-level burden to women's health arising from these risk loci is highly significant considering the incidence of the condition. Together with the recent progress in molecular tumor characterization and subclassification, the identification of the genetic components of UL predisposition should pave the way towards more sophisticated prevention and management strategies for these extremely common tumors. The risk SNP with the most immediate potential value is that at estrogen receptor alpha, and our findings should fuel much further work on the interplay between individual germline genetics, endogenous and exogenous hormonal exposure, and occurrence and growth rate of UL.
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